COMPARATIVE ANALYSIS OF QUANTITATIVE COMPUTED TOMOGRAPHY DATA AND HISTOLOGICAL FINDINGS IN PATIENTS WITH GIANT CELL BONE TUMOR TREATED WITH DENOSUMAB
Background. Giant cell tumor of bone (GCTB) is a common benign lesion accounting for 4–9.5 % of all primary bone tumors. Although surgery is considered the method of choice in the treatment of GCT, however, denosumab, a genetically engineered drug with a novel mechanism of action, has been recently...
Saved in:
| Main Authors: | S. A. Tabakaev, I. G. Frolova, I. I. Anisenya, N. V. Vasilyev, A. V. Bogoutdinova, P. K. Sitnikov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2021-05-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/1751 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combined use of 3D-printed customized prostheses and denosumab for the treatment of giant cell tumor of the distal radius: clinical outcomes and efficacy
by: Ye Li, et al.
Published: (2025-08-01) -
Denosumab is the first gene engineered agent for the treatment of osteoporosis
by: O A Nikitinskaya, et al.
Published: (2012-09-01) -
EFFECT OF DENOSUMAB ON CLINICAL AND RADIOLOGICAL CHANGES IN RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS
by: P. S. Dydykina, et al.
Published: (2015-04-01) -
A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis
by: Yasumori Sobue, et al.
Published: (2025-07-01) -
Denosumab in patients with osteogenesis imperfecta and a historical control study with alendronate
by: Yazhao Mei, et al.
Published: (2025-05-01)